Hoth Therapeutics (NASDAQ:HOTH) Announces Quarterly Earnings Results

Hoth Therapeutics (NASDAQ:HOTH) announced its quarterly earnings results on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01), Zacks reports.

Hoth Therapeutics Price Performance

NASDAQ:HOTH traded down $0.05 during trading hours on Friday, reaching $0.80. 140,312 shares of the company traded hands, compared to its average volume of 1,389,181. The firm’s 50-day moving average is $0.92 and its 200-day moving average is $0.93. The stock has a market cap of $5.51 million, a P/E ratio of -0.59 and a beta of 0.84. Hoth Therapeutics has a 1-year low of $0.58 and a 1-year high of $1.73.

Analyst Ratings Changes

Several equities analysts recently weighed in on HOTH shares. Benchmark reaffirmed a “speculative buy” rating and issued a $3.00 price objective on shares of Hoth Therapeutics in a research note on Friday, October 11th. HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Hoth Therapeutics in a research report on Monday, November 4th. Finally, EF Hutton Acquisition Co. I upgraded shares of Hoth Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 21st.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.